Nevro (NVRO)
(Delayed Data from NYSE)
$4.92 USD
+0.09 (1.86%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $4.90 -0.02 (-0.41%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.92 USD
+0.09 (1.86%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $4.90 -0.02 (-0.41%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Zacks News
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
by Zacks Equity Research
Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform
by Zacks Equity Research
Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 31.75% and 2.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 17.72% and 4.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Why Is Nevro (NVRO) Down 8.8% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 31.37% and 3.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 Medical Device Stocks Beat This Earnings Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.
Abbott (ABT) Expands in Canada With First Eterna SCS Use
by Zacks Equity Research
Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
by Zacks Equity Research
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 70% and 0.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
by Zacks Equity Research
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
Inogen (INGN) Down 4.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.